| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
CJ-042794 (CJ-042794) is a a novel, potent, and selective prostaglandin EP(4) receptor antagonist, with a mean pKi of 8.5, a binding affinity that was at least 200-fold more selective for the human EP4 receptor than other human EP receptor subtypes (EP1, EP2, and EP3).
| Targets |
EP ( EC50 = 10 nM )
|
|---|---|
| ln Vitro |
CJ-042794 (CJ-042794, 0.3-5000 nM; 10 min; hEP4/HEK293 cells) shows concentration-dependent inhibition of the PGE2-induced elevation of cAMP with a pIC50 value of 7.5[1].
CJ-042794 (3-3000 nM; 24 h) CJ-042794 reverses the inhibitory effects of PGE2 (10 nM) on the LPS-induced production of TNFα in human whole blood (HWB), with a pIC50 value of 6.4 in a concentration-dependent manner[1]. |
| ln Vivo |
CJ-042794 (CJ-042794; 0.3-3 mg/kg; i.d.; once) inhibits AE1-329'sHCO3stimulatory action in the duodenum[1].
CJ-042794 (30 and 50 mg/kg; p.o.; once) has no gastric ulcerogenic response and does not harm the gastric mucosa of normal rats in response to cold-restraint stress[1]. CJ-042794 (30 and 50 mg/kg; p.o.; once) does not harm helper arthritis rats' stomachs or small intestines[1]. CJ-042794 (3-45 mg/kg; p.o.; twice daily for 14 d; Sprague-Dawley rats) promotes spontaneous healing of gastric ulcers[1]. The repeated administration of CJ-042794 (10 mg/kg; p.o.; daily, for 7 d) inhibits the healing process of chronic gastric ulcers by downregulating the expression of vascular endothelial growth factor in the ulcerated mucosa[1]. |
| Animal Protocol |
Male Sprague-Dawley rats (200-230 g)
0.3, 1, and 3 mg/kg intradermal injection; once |
| References |
|
| Additional Infomation |
Benzoic acid, 4-[(1s)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]- is an aromatic ether.
|
| Molecular Formula |
C22H17CLFNO4
|
|---|---|
| Molecular Weight |
413.8261
|
| Exact Mass |
413.083
|
| Elemental Analysis |
C, 63.85; H, 4.14; Cl, 8.57; F, 4.59; N, 3.38; O, 15.46
|
| CAS # |
847728-01-2
|
| PubChem CID |
11524454
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
572.7±50.0 °C at 760 mmHg
|
| Flash Point |
300.2±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.616
|
| LogP |
5.91
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
561
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C1C=CC(F)=CC=1)C1=CC=C(Cl)C=C1C(=O)N[C@H](C1C=CC(C(=O)O)=CC=1)C
|
| InChi Key |
MWBNCZHVEXULBD-ZDUSSCGKSA-N
|
| InChi Code |
InChI=1S/C22H17ClFNO4/c1-13(14-2-4-15(5-3-14)22(27)28)25-21(26)19-12-16(23)6-11-20(19)29-18-9-7-17(24)8-10-18/h2-13H,1H3,(H,25,26)(H,27,28)/t13-/m0/s1
|
| Chemical Name |
4-[(1S)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]benzoic acid
|
| Synonyms |
CJ-042794; CJ-042794; CJ-042794; RQ-00015986; RQ-15986
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 28 mg/mL (~67.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.04 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4165 mL | 12.0823 mL | 24.1645 mL | |
| 5 mM | 0.4833 mL | 2.4165 mL | 4.8329 mL | |
| 10 mM | 0.2416 mL | 1.2082 mL | 2.4165 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA